Cathepsin B Level, Pentraxin 3 Level, Pre-Eclampsia
Conditions
Keywords
second trimester, preeclampsia, pentraxin 3, Cathepsin B
Brief summary
In this study, the investigator aim was to compare Cathepsin B and Pentraxin 3 levels measured from maternal serum of pregnant women diagnosed with preeclampsia in the second trimester, the effects of these levels on maternal/ fetal outcomes and the composite results of Cathepsin B and Pentraxin 3 levels alone or together and contribute to the literature in this area.
Detailed description
This prospective case-control study was conducted between 1 January 2022 and 31 December 2022 at Bursa Yuksek Ihtisas Training and Research Hospital. The study was conducted with pregnant women between ages of 18-45 who were diagnosed with preeclampsia in the second trimester. This study was conducted with total 156 pregnant women. participants were grouped according to the presence of preeclampsia; Group1: Patients diagnosed with preeclampsia between 20-28 weeks (study group) (n:78) , Group 2: Healthy pregnant women between 20-28 weeks without a diagnosis of preeclampsia ( control group) (n:78) . As soon as preeclampsia is diagnosed and before any treatment was started, maternal serum samples were collected in the Cathepsin B and Pentraxin 3 kit in amounts suitable for the study. The samples obtained were kept in biochemistry laboratory at -80 degrees until the study was conducted. After all samples were collected, Cathepsin B and Pentraxin 3 values were measured by ELISA method.
Interventions
OTHERCathepsin B and pentraxin 3 levels in preeclampsia with pregnant women
The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia
Sponsors
Sanliurfa Mehmet Akif Inan Education and Research Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Singleton pregnancy * Pregnant women diagnosed with preeclampsia between 20-28 weeks of gestation * Healthy pregnant women between 20-28 weeks of gestation who want to be involved in the study.
Exclusion criteria
* Multiple pregnancies * Pregnant women who gave birth below 24 weeks of gestation * Pregnant women diagnosed with other hypertensive diseases of pregnancy other than preeclampsia ( gestational hypertension, chronic hypertension, superimposed hypertension) * Pregnant women with chromosomal or congenital anomalies in the fetus * Women with a known infective or autoimmune disease before pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of the effects and composite results of cathepsin b and pentraxin 3 levels in pregnant women diagnosed with preeclampsia | 12 months | serum cathepsin b (nmoL pNA/mL) and serum pentraxin 3 (ng/ml) levels composite results on pregnant women diagnosed with preeclampsia |
Countries
Turkey (Türkiye)
Outcome results
None listed